Leukemia

Clinical decision-making based on minimal residual disease may be associated with improved therapy satisfaction and optimized post-remission treatment for patients with intermediate-risk acute myeloid leukemia.

A recent study provides evidence showing that focal 22q11.22 deletions may be correlated with poor outcomes in patients with pediatric B-cell acute lymphoblastic leukemia with alterations in IKZF1.

After implementing disparity and demographic reporting in acute leukemia clinical trials, investigators did not report an increase in diverse trial participants.

Pediatric patients with low-risk acute lymphoblastic leukemia may be able to omit treatment with vincristine and dexamethasone pulse therapy after the first year of treatment.

The risk of infection during induction chemotherapy decreased among patients with acute myeloid leukemia treated with romyelocel-L.

Compared with anti-thymocyte globulin, post-transplant cyclophosphamide appears to more successfully prevent graft-versus-host disease in patients with acute lymphoblastic leukemia, resulting in a lower incidence of relapse and improved survival.

Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma were pretreated with ibrutinib saw a reduction in obinutuzumab-induced infusion-related reactions as well as cytokines and chemokines.

A systemic review and network meta-analysis investigated 3 trials and determined that acalabrutinib/obinutuzumab up front prolongs progression-free survival for patients with chronic lymphocytic leukemia vs other regimens.

A study published in Lancet Oncology indicated that children with low-risk acute lymphoblastic leukemia may be able to safely omit pulse therapy after 1-year of treatment.

Pediatric and adolescent patients with acute lymphoblastic leukemia experienced similar outcomes when treated with either calaspargase pegol or pegaspargase.

Eytan Stein, MD, considers promising, new therapeutic options for adult patients with acute myeloid leukemia.

Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.

An expert lists the information physicians consider when choosing a first-line therapy for patients with chemotherapy-ineligible acute myeloid leukemia.

Eytan Stein, MD, discusses the predictive and prognostic factors for patients with chemotherapy-ineligible acute myeloid leukemia.

An expert explains the first-line treatment options for patients with chemotherapy-ineligible acute myeloid leukemia.

Dr Stein elaborates on the impact of the approval of small molecule inhibitors for the treatment of acute myeloid leukemia.

Eytan Stein, MD, discusses the therapeutic standards of care for newly diagnosed adult patients with acute myeloid leukemia.

Combination ivosidenib/azacitidine has yielded notable improvements in survival over ivosidenib alone in IDH1-positive treatment-naïve acute myeloid leukemia.

Older adult patients with newly diagnosed high-risk or secondary acute myeloid leukemia experienced a durable survival benefit when treated with CPX-351 over 7+3 cytarabine and daunorubicin chemotherapy.

The SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab for patients with treatment-naïve chronic lymphocytic leukemia demonstrated superior progression-free survival results with the BTK inhibitor.

Patients with Philadelphia chromosome–negative acute lymphocytic leukemia who have hypersensitivity to pegylated asparaginase may benefit from eryaspase treatment.

A phase 1/2 trial featuring lanraplenib/gilteritinib in patients with FLT3-mutant acute myeloid leukemia will proceed following the FDA’s clearance of an investigational new drug application.

CancerNetwork® sat down with Julie Vose, MD, MBA, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about a clinical trial comparing acalabrutinib versus ibrutinib for patients with chronic lymphocytic leukemia.

CancerNetwork® spoke with Jeffery Auletta, MD, about how the National Marrow Donor Program/Be The Match is using research initiatives to expand eligibility for stem cell transplants in for patient with acute leukemias and myelodysplastic syndrome.

Results of a phase 2 trial show that ibrutinib was capable of inducing responses in some patients with hairy cell leukemia who were previously treated with standard therapy options in a prior line.

The phase 2 GIMEMA LAL1913 trial identified poor outcomes and increased minimal residual disease persistence among patients with Philadelphia-like acute lymphoblastic leukemia.

A new study has adapted CAR to look more human to the body, which will then in turn yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

The updated results of an ongoing phase 1/2 study indicated that CA-4948 achieved promising responses and a tolerable safety profile in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

In a trial of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and other hematologic cancers, the BCL-2 inhibitor lisaftoclax demonstrated feasibility as a treated option in the relapsed or refractory setting.

Ibrutinib and venetoclax may prove beneficial in previously untreated chronic lymphocytic leukemia.